Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP).
In 1995, highly effective inactivated hepatitis A vaccines were first licensed in the United States for preexposure prophylaxis against hepatitis A virus (HAV) among persons aged > or =2 years. In 2005, vaccine manufacturers received Food and Drug Administration approval for use of the vaccines in children aged 12-23 months.
D006506:Hepatitis A / Q000517:prevention & control* / Q000635:transmission; D022362:Hepatitis A Vaccines / Q000008:administration & dosage*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D014195:Travel
D022362:Hepatitis A Vaccines; D016756:Immunoglobulins, Intravenous